Filtered By:
Cancer: Ovarian Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 759 results found since Jan 2013.

Current Development of siRNA Bioconjugates: From Research to the Clinic
In this study, it was shown that the main factor determining the nature of the biodistribution of conjugates is their lipophilicity. Conjugates of siRNA with lower lipophilicity; i.e., derivatives of retinoic acid, lithocholic acid, and docosahexanoic acid with greater efficiency than cholesterol conjugates accumulated in the kidneys, bladder, and lungs of the mouse after subcutaneous injection (Biscans et al., 2018). This fact is consistent with previous data that showed that more lipophilic conjugates bind more efficiently to serum components, and thus are not excreted by the kidneys (Wolfrum et al., 2007; Osborn et al.,...
Source: Frontiers in Pharmacology - April 25, 2019 Category: Drugs & Pharmacology Source Type: research

Knockdown of STAT3 expression in SKOV3 cells by biodegradable siRNA-PLGA/CSO conjugate micelles.
Abstract Biodegradable and biocompatible poly(d,l-lactic-co-glycolic acid) (PLGA)was conjugated to the 5'-thiol end of signal transducer and activator of transcription 3 (STAT3) small interfering RNA (STAT3-siRNA) via a disulfide bond. In aqueous environments, these siRNA-PLGA conjugates can spontaneously form core/shell type spherical micelles with a particle size of about 200nm. A biodegradable, low molecular weight cationic polymer, chitosan oligosaccharide (CSO), was added to the siRNA-PLGA micelles at different nitrogen to phosphate (N/P) ratios to form stable, spherical siRNA-PLGA/CSO micelles with sizes of ...
Source: Colloids and Surfaces - January 28, 2015 Category: Biotechnology Authors: Zhao Y, Zheng C, Zhang L, Chen Y, Ye Y, Zhao M Tags: Colloids Surf B Biointerfaces Source Type: research

PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy.
Abstract Although siRNA-mediated downregulation technology has been highly successful in suppressing the expression of any disease-related gene, systemic delivery of siRNA for the clinical applications remains challenging, especially in the use of cancer therapy. DC-Chol/DOPE cationic liposomes as one of the most attractive vehicles for gene delivery have been widely exploited for transfection of siRNA into cells, but complexity of systemic delivery has allowed only their direct injection into local targets due to the formation of aggregations with negatively-charged blood components. Herein, we demonstrate the ef...
Source: Biochemical and Biophysical Research communications - July 23, 2018 Category: Biochemistry Authors: Lee J, Ahn HJ Tags: Biochem Biophys Res Commun Source Type: research

Abstract LB-103: L1CAM-targeted delivery of siRNA using elastin-like polypeptide (ELP) nanoparticles inhibits the growth of human tumors implanted in mice
Small interfering RNA (siRNA) drugs provide ideal means for perturbing intracellular oncogenic targets. However, specific delivery of siRNA to tumors has proven to be difficult. An ELP was engineered with an N-terminal region that binds to L1 cell adhesion molecule (L1CAM), and a C-terminal region that binds siRNA. Upon binding of siRNA, the L1CAM targeted ELP (ELP-L) spontaneously assembled into a spherical nanocomplex with the siRNA protected within, and the CAM-binding region protruding from the surface. These nanoparticles were used to deliver siRNA to SKOV3 tumors formed following surgical implantation of the cells in...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Primiano, T., Chang, B.-D., Heidel, J. D. Tags: Experimental and Molecular Therapeutics Source Type: research

Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Co-polymer to Overcome TLR4 Driven Chemotherapy Resistance.
This study demonstrates that PEI-g-PCL-b-PEG-Fol conjugates are a reliable delivery system for siRNA and are able to mediate therapeutic protein knockdown within ovarian cancer cells. Additionally, this study provides further evidence to link TLR4 levels to chemotherapy resistance. PMID: 26636884 [PubMed - as supplied by publisher]
Source: Biomacromolecules - December 4, 2015 Category: Biochemistry Authors: Jones SK, Lizzio V, Merkel O Tags: Biomacromolecules Source Type: research

Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route.
Authors: Meryet-Figuière M, Lecerf C, Varin E, Coll JL, Louis MH, Dutoit S, Giffard F, Blanc-Fournier C, Hedir S, Vigneron N, Brotin E, Pelletier L, Josserand V, Denoyelle C, Poulain L Abstract Ovarian cancer is the leading cause of death from gynecological malignancies worldwide, and innate or acquired chemoresistance of ovarian cancer cells is the major cause of therapeutic failure. It has been demonstrated that the concomitant inhibition of Bcl-xL and Mcl-1 anti-apoptotic activities is able to trigger apoptosis in chemoresistant ovarian cancer cells. In this context, siRNA-mediated Bcl‑xL and Mcl-1 inhibition...
Source: Oncology Reports - August 11, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer
Conclusion: Our findings demonstrated the Py-TPE/siRNA@PMP as a promising agent for the highly efficient treatment of PTX-resistant cells and overcoming the shortage of chemotherapy in ovarian cancer.
Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Jun Wu, Quan Wang, Xiaoqi Dong, Min Xu, Juliang Yang, Xiaoqing Yi, Biao Chen, Xiyuan Dong, Ying Wang, Xiaoding Lou, Fan Xia, Shixuan Wang, Jun Dai Tags: Research Paper Source Type: research

Abstract LB-13: Hyaluronic acid-based CD44 targeted nanoparticle delivery of combination MDR1 siRNA/paclitaxel to overcome drug resistance in ovarian cancer
A major obstacle in the success of chemotherapy in ovarian cancer is the emergence of multidrug resistance (MDR). Overexpression of the MDR1 gene and corresponding P-glycoprotein (Pgp) efflux pumps is one of the best characterized MDR mechanisms. Although MDR1 siRNA based strategies are emerging as highly promising approaches to reverse MDR, the systemic delivery still remains a great challenge. In the present study, CD44 targeting hyaluronic acid (HA) based self-assembling nanoparticle systems were designed with MDR1 siRNA to evaluate its delivery efficiency and combination anticancer therapeutic efficacy with paclitaxel ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Yang, X., lyer, A., hornicek, F., Amiji, M., Duan, Z. Tags: Cancer Chemistry Source Type: research

SiRNA-Mediated RRM2 Gene Silencing Combined with Cisplatin in the Treatment of Epithelial Ovarian Cancer In Vivo: An Experimental Study of Nude Mice.
Discussion: siRNA alone or combined with cisplatin can effectively inhibit the growth of human ovarian cancer in nude mice models of subcutaneous transplantation of tumor cells. RRM2 gene silencing may be a potential treatment regimen for ovarian cancer in future. PMID: 31673243 [PubMed - in process]
Source: International Journal of Medical Sciences - November 2, 2019 Category: Biomedical Science Tags: Int J Med Sci Source Type: research

Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer
Conclusions These findings suggest that this CD44 targeted HA-PEI/HA-PEG nanoparticle platform may be a clinicaly relevant gene delivery system for systemic siRNA-based anticancer therapeutics for the treatment of MDR cancers.
Source: Pharmaceutical Research - December 17, 2014 Category: Drugs & Pharmacology Source Type: research

Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model
Publication date: Available online 10 February 2019Source: Journal of Pharmacological SciencesAuthor(s): Mai Hazekawa, Takuya Nishinakagawa, Tomoyo Kawakubo-Yasukochi, Manabu NakashimaAbstractSmall interfering RNA (siRNA) has received much attention and for possible therapeutic applications to treat incurable chronic and genetic diseases, including cancer. However, the development of safe and efficient carriers for siRNA delivery still remains formidable hurdles for in vivo. The purpose of this study is to prepare siRNA–PLGA hybrid micelles to deliver the siRNA into the ovarian cancer cells and to evaluate of gene silenc...
Source: Journal of Pharmacological Sciences - February 11, 2019 Category: Drugs & Pharmacology Source Type: research

Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy.
Abstract For effective ovarian cancer gene therapy, systemic administrated tumor-targeting siRNA/folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate (FA-PEG-COL) nanoparticles is vital for delivery to cancer site(s). siRNA/FA-PEG-COL nanoparticles were prepared by ionic gelation for effective FA receptor-expressing ovarian cancer cells transfection and in-vivo accumulation. The chemical structure of FA-PEG-COL conjugate was characterized by MALDI-TOF-MS, FT-IR and H(1) NMR. The average size of siRNA/FA-PEG-COL nanoparticles was approximately 200 nm, and the surface charge was +8.4 mV compared to +30....
Source: European Journal of Pharmaceutical Sciences - October 28, 2013 Category: Drugs & Pharmacology Authors: Li TS, Yawata T, Honke K Tags: Eur J Pharm Sci Source Type: research

Abstract 3761: Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
Ovarian cancer is the deadliest of gynecological cancers in the United States. With fewer than 15% of cases diagnosed early, ovarian cancer continues to be characterized by late-stage presentation. Treatment for ovarian cancer usually involves surgical cytoreduction followed by platinum-based chemotherapy. Unfortunately, despite initial respond, more than 70% of ovarian cancer patients develop cisplatin resistance, relapse and therapeutic failure. Therefore, there is a need of novel therapies focused on targets within cancer cell survival pathways for advanced stage drug resistant ovarian cancer. Evidence indicates that ac...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Reyes–Gonzalez, J. M., Armaiz, G. N., Mangala, L. S., Valiyeva, F., Pradeep, S., Sood, A. K., Vivas–Meȷia, P. E. Tags: Experimental and Molecular Therapeutics Source Type: research

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Authors: Palanca-Wessels MC, Booth GC, Convertine AJ, Lundy BB, Berguig GY, Press MF, Stayton PS, Press OW Abstract The therapeutic potential of RNA interference (RNAi) has been limited by inefficient delivery of short interfering RNA (siRNA). Tumor-specific recognition can be effectively achieved by antibodies directed against highly expressed cancer cell surface receptors. We investigated the utility of linking an internalizing streptavidin-conjugated HER2 antibody to an endosome-disruptive biotinylated polymeric nanocarrier to improve the functional cytoplasmic delivery of siRNA in breast and ovarian cancer cell...
Source: Oncotarget - February 4, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Calcium-doped mesoporous silica nanoparticles as a lysosomolytic nanocarrier for amine-free loading and cytosolic delivery of siRNA
Publication date: 25 January 2020Source: Journal of Industrial and Engineering Chemistry, Volume 81Author(s): Eunshil Choi, Dong-Kwon Lim, Sehoon KimAbstractFor efficacious gene therapeutics, cytosolic transport of the endocytosed siRNA is crucial, not to mention a non-toxic delivery carrier composition. In this paper, we report facile achievement of amine-free loading and lysosomolytic delivery of siRNA in an unconventional way by using calcium (Ca2+)-doped mesoporous silica nanoparticles (CMSNs) as a host material along with a pore-loaded endosomal disruptor, chloroquine (CQ). It is demonstrated that CMSNs are capable of...
Source: Journal of Industrial and Engineering Chemistry - November 16, 2019 Category: Chemistry Source Type: research